Commentary: BioShield patent enlargement will raise drug prices

09/29/2005 | Washington Times, The

A former U.S. budget official says last year's BioShield legislation was intended to promote drug availability to counter biological and other terror threats but instead encourages higher drug prices. J.T. Young, writing in The Washington Times, says drugmakers are seeking patent enlargement under the guise of responding to bioterrorism and the result may be more expensive drugs and a disincentive to adopt cost-saving health information technology.

View Full Article in:

Washington Times, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC